Results 21 to 30 of about 38,769 (305)

Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors [PDF]

, 2022
Aim: The organ protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors may be beneficial against infectious complications. This real-world study aims to compare the risk of pneumonia and sepsis between SGLT2 inhibitors and dipeptidyl ...
Yu, Shuk Yin, Chan, Yap Hang, Li, Hang Long, Tse, Yi Kei, Wu, Mei Zhen, Chandramouli, Chanchal, Wong, Pui Fai, Tse, Hung Fat, Lam, Carolyn S.P., Yiu, Kai Hang, Yu, Si Yeung, Ren, Qing Wen   +11 more
core   +1 more source

The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study

Medicines, 2022
Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial.
Suriyon Uitrakul, Krittika Aksonnam, Pimchanok Srivichai, Sorawit Wicheannarat, Supatcha Incomenoy   +4 more
doaj   +1 more source

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents [PDF]

, 2014
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
core   +1 more source

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus

Cardiovascular Diabetology, 2022
Background There have been scarce data comparing cardiovascular outcomes between individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the subsequent cardiovascular risk between individual SGLT2 inhibitors. Methods We analyzed
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro   +15 more
doaj   +1 more source

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.

JAMA
Importance  Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce chronic kidney disease (CKD) progression in individuals with type 2 diabetes, CKD, or heart failure.
Neuen BL, Fletcher RA, Anker SD, Bhatt DL, Butler J, Cherney DZI, Docherty KF, Inzucchi SE, Jardine MJ, Mahaffey KW, McCausland FR, McGuire DK, McMurray JJV, Neal B, Packer M, Patel SM, Perkovic V, Sabatine MS, Sardell RJ, Solomon SD, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Haynes R, Staplin N, Herrington WG, Heerspink HJL, SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C).   +28 more
europepmc   +2 more sources

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes

, 2022
The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks.
Li, Lifang, Tse, Gary, Liu, Xuejin, Jing, Fengshi, Cheung, Bernard Man Yung, Wong, Wing Tak, Zhang, Qingpeng, Chou, Oscar Hou-In, Liu, Tong, Chang, Carlin, Lee, Sharen, Zhou, Jiandong   +11 more
core   +1 more source

Treatment response to SGLT2 inhibitors

, 2021
SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety
Jasna Klen, Vita Dolžan, Klen, Jasna, Dolžan, Vita   +3 more
core   +1 more source

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology

Frontiers in Cardiovascular Medicine, 2022
PurposeSodium-glucose cotransporter 2 (SGLT2) inhibitors have cardiorenal protective effects regardless of whether they are combined with type 2 diabetes mellitus, but their specific pharmacological mechanisms remain undetermined.Materials and MethodsWe ...
Anzhu Wang, Anzhu Wang, Zhendong Li, Sun Zhuo, Feng Gao, Feng Gao, Hongwei Zhang, Hongwei Zhang, Zhibo Zhang, Zhibo Zhang, Gaocan Ren, Gaocan Ren, Xiaochang Ma, Xiaochang Ma   +13 more
doaj   +1 more source

Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials

Therapeutic Advances in Chronic Disease, 2022
Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce serum urate in patients with type 2 diabetes mellitus. To evaluate if this effect applies to both patients with and without diabetes, we conducted a systematic review
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, Yao Neng Teo, Nicholas L. X. Syn, Ray Meng See, Caitlin Fern Wee, Elliot Yeung Chong, Chi-Hang Lee, Mark Y. Chan, Tiong-Cheng Yeo, Raymond C. C. Wong, Ping Chai, Ching-Hui Sia   +13 more
doaj   +1 more source

Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos [PDF]

, 2022
Sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin has been found to increase the risk for lowerlimb amputations in type 2 diabetics about two-fold. Conversely, empagliflozin and dapagliflozin do not display a similar effect.
Hjelt Anja, Paatero Ilkka, Haapanen-Saaristo Anna-Mari, Huttunen Roope, Määttä Jorma, Järveläinen Hannu, Rummukainen Petri, Sainio Annele   +7 more
core   +1 more source